Status:
UNKNOWN
Real World Outcomes Using Novel Agents for AML in the UK
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborating Sponsors:
King's College London
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
16+ years
Brief Summary
This project will collect data on patients with acute myeloid leukemia in the United Kingdom who were treated with two new targeted therapies during the coronavirus pandemic
Detailed Description
Acute myeloid leukaemia (AML) is a blood cancer which in fit young adults is typically treated with intensive chemotherapy. While this is potentially curative, it is associated with significant side e...
Eligibility Criteria
Inclusion
- Venetoclax cohort Inclusion criteria
- Newly diagnosed acute myeloid leukaemia
- No prior therapies for AML, apart from hydroxyurea (or similar) for cytoreduction. Previous treatments for MDS or other conditions are allowed
- Treated with venetoclax in combination with either azacitidine or LDAC No exclusion criteria
- Gilteritinib/FLT3 cohort Inclusion criteria
- Relapsed acute myeloid leukaemia, including molecular relapse
- Treated with FLT3 inhibitor No exclusion criteria
Exclusion
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05312112
Start Date
May 1 2022
End Date
October 1 2023
Last Update
March 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom, SE1 9RT